Entropy Neurodynamics

Entropy Neurodynamics Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Entropy Neurodynamics (ENP.AX) as of Nov 22, 2026 is -2,892.40. In the previous year, Cash Conversion Cycle (CCC) was -1,481.57 — a change of 95.22% (lower).

Cash Conversion Cycle

-2,892.40

YoY

95.22%

Last updated:

Cash Conversion Cycle (CCC) of Entropy Neurodynamics is 2026 -2,892.40 . Cash Conversion Cycle (CCC) of Entropy Neurodynamics was 2025 -1,481.57 . It decreases by 95.22% lower compared to the previous year.

The Entropy Neurodynamics Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
-44,709.68 AUD
Jan 1, 2019
-222.18 AUD
Jan 1, 2020
-131.35 AUD
Jan 1, 2021
-111.14 AUD
Jan 1, 2024
-68,415.21 AUD
Jan 1, 2025
-1,481.57 AUD
Jan 1, 2026
-2,892.40 AUD
The Entropy Neurodynamics Cash Conversion Cycle history
YEARCash Conversion CycleYoY
-2,892.40+95.22%
-1,481.57-97.83%
-68,415.21+61,457.74%
-111.14-15.38%
-131.35-40.88%
-222.18-99.50%
-44,709.68—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entropy Neurodynamics Stock analysis

What does Entropy Neurodynamics do? Entropy Neurodynamics Ltd develops and commercializes exosomes as therapeutic agents. The company holds intellectual property related to exosome technology and offers LEAP manufacturing, LOAD API loading, and EVPS tropism technologies. Pharmaceutical and biotechnology companies purchase these proprietary technologies to enhance their own exosome-based products. The firm invests in biopharmaceutical drug development and leverages its portfolio of know-how to support partners in exosome medicine development. Exopharm Ltd. is the company's brand name, and it operates through its exosome technology portfolio. The firm's technologies solve key challenges in exosome medicine success, including manufacturing efficiency and targeted delivery. Biopharmaceutical companies are the primary buyers of these technologies, seeking to integrate exosome delivery systems into their therapeutic pipelines. The company's business model centers on licensing its exosome-related IP and know-how to pharmaceutical and biotech firms. By providing LEAP, LOAD API, and EVPS technologies, Entropy Neurodynamics enables partners to overcome technical barriers in exosome-based drug development. This approach generates revenue through technology licensing agreements with industry partners. Entropy Neurodynamics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entropy Neurodynamics stock

Cash Conversion Cycle (CCC) of Entropy Neurodynamics is -2,892.40 in 2026.

Cash Conversion Cycle (CCC) of Entropy Neurodynamics changed from -1,481.57 to -2,892.40, representing a 95.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Entropy Neurodynamics since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Entropy Neurodynamics with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Entropy Neurodynamics

All Key Metrics — Entropy Neurodynamics